Impact of Smoking on Circulating Cardiac Troponin i Concentrations and Cardiovascular Events in the General Population: The HUNT Study (Nord-Trøndelag Health Study)

Circulation

Volumn 134, Issue 24, 2016, Pages 1962-1972

  Lyngbakken, Magnus Nakrem ^a   Skranes, Julia Brox ^a   De Lemos, James A ^b   Nygård, Ståle ^c   Dalen, Håvard ^d,e,f   Hveem, Kristian ^f   Røsjø, Helge ^a   Omland, Torbjørn ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e Nord Trøndelag Hospital Trust HNT   (Norway)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

cardiovascular diseases; epidemiology; prevention and control; risk assessment; smoking; troponin

Indexed keywords

TOBACCO SMOKE; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FRAMINGHAM RISK SCORE; HEART FAILURE; HEART MUSCLE FIBROSIS; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NORWAY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SMOKING; AREA UNDER THE CURVE; BLOOD; CARDIOVASCULAR DISEASES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SELF REPORT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE; SELF REPORT; SEX FACTORS; SMOKING; TROPONIN I; YOUNG ADULT;

EID: 84994641779     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.023726     Document Type: Article

References (44)

1. World Health Organization. Report on the global tobacco epidemic, 2008: the MPOWER package. 2008. http://whqlibdoc.who.int/publications/2008/9789241596282-eng.pdf. Accessed February 18, 2016.
2. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. 2009. http://www.who.int/entity/healthinfo/global-burden-disease/Global-HealthRisks-report-full.pdf. Accessed February 19, 2016.
3. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43:1731-1737. doi: 10.1016/j.jacc.2003.12.047.
4. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567. doi: 10.1093/eurheartj/ehs184.
5. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, Woodward M, Struthers A, Hughes M, Kee F, Salomaa V, Kuulasmaa K, Blankenberg S; MORGAM Investigators. High population prevalence of cardiac troponin I measured by a highsensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2014;35:271-281. doi: 10.1093/eurheartj/eht406.
6. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367-1376. doi: 10.1161/CIRCULATIONAHA.110.005264.
7. Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA. Age-and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014;63:1441-1448. doi: 10.1016/j. jacc.2013.12.032.
8. Omland T, de Lemos JA, Holmen OL, Dalen H, Benth JŠ, Nygård S, Hveem K, Røsjø H. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. Clin Chem. 2015;61:646-656. doi: 10.1373/clinchem.2014.234369.
9. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, Bratberg G, Heggland J, Holmen J. Cohort profile: the HUNT Study, Norway. Int J Epidemiol. 2013;42:968-977. doi: 10.1093/ije/dys095.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497. doi: 10.1001/jama.285.19.2486.
11. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753. doi: 10.1161/CIRCULATIONAHA. 107.699579.
12. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54-61. doi: 10.1373/clinchem.2011.165795.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. doi: 10.7326/0003-4819-130-6-199903160-00002.
14. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21. doi: 10.1002/sim.4085.
15. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem. 2012;58:1574-1581. doi: 10.1373/clinchem.2012.192716.
16. Nadruz W Jr, Gonçalves A, Claggett B, Querejeta Roca G, Shah AM, Cheng S, Heiss G, Ballantyne CM, Solomon SD. Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Heart Fail. 2016;18:629-637. doi: 10.1002/ejhf.511.
17. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-2512. doi: 10.1001/jama.2010.1768.
18. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494-2502. doi: 10.1001/jama.2010.1708.
19. Raupach T, Schäfer K, Konstantinides S, Andreas S. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J. 2006;27:386-392. doi: 10.1093/eurheartj/ehi601.
20. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368:647-658. doi: 10.1016/S0140-6736(06)69249-0.
21. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86-97. doi: 10.1001/jama.290.1.86.
22. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial in healthy men. Lancet. 1981;2:1303-1310. doi: 10.1016/S0140-6736(81)91338-6.
23. Bella JN, Devereux RB, Roman MJ, O'Grady MJ, Welty TK, Lee ET, Fabsitz RR, Howard BV. Relations of left ventricular mass to fatfree and adipose body mass: the strong heart study: the Strong Heart Study Investigators. Circulation. 1998;98:2538-2544. doi: 10.1161/01.cir.98.23.2538.
24. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88:389-419. doi: 10.1152/physrev. 00017.2007.
25. Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014;164:323-335. doi: 10.1016/j.trsl.2014.05.001.
26. Kawasaki T, Sakai C, Harimoto K, Yamano M, Miki S, Kamitani T. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:867-872. doi: 10.1016/j.amjcard.2013.04.060.
27. Payne JR, James LE, Eleftheriou KI, Hawe E, Mann J, Stronge A, Banham K, World M, Humphries SE, Pennell DJ, Montgomery HE. The association of left ventricular mass with blood pressure, cigarette smoking and alcohol consumption: data from the LARGE Heart study. Int J Cardiol. 2007;120:52-58. doi: 10.1016/j.ijcard. 2006.08.043.
28. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, Hundley WG, Lima JA, Bluemke DA. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol. 2006;48:2285-2292. doi: 10.1016/j.jacc.2006.03.072.
29. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond). 2008;32:959-966. doi: 10.1038/ijo.2008.11.
30. Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, Khaw KT. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obes Res. 2005;13:1466-1475. doi: 10.1038/oby.2005.177.
31. Moreno V, Hernández-Romero D, Vilchez JA, García-Honrubia A, Cambronero F, Casas T, González J, Martínez P, Climent V, de la Morena G, Valdés M, Marín F. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail. 2010;16:950-956. doi: 10.1016/j. cardfail.2010.07.245.
32. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E; PEACE Investigators. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013;61:1240-1249. doi: 10.1016/j.jacc.2012.12.026.
33. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E; Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538-2547. doi: 10.1056/NEJMoa0805299.
34. Gourlay SG, Rundle AC, Barron HV. Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res. 2002;4:101-107. doi: 10.1080/14622200110103205.
35. Ali SF, Smith EE, Bhatt DL, Fonarow GC, Schwamm LH. Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischemic stroke. J Am Heart Assoc. 2013;2:e000171. doi: 10.1161/JAHA.113.000171.
36. Pollock JS, Hollenbeck RD, Wang L, Janz DR, Rice TW, McPherson JA. A history of smoking is associated with improved survival in patients treated with mild therapeutic hypothermia following cardiac arrest. Resuscitation. 2014;85:99-103. doi: 10.1016/j. resuscitation.2013.08.275.
37. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Nunez E, Yancy CW, Young JB. A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J. 2008;29:1983-1991. doi: 10.1093/eurheartj/ehn210.
38. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138. doi: 10.1016/j.jacc.2009.09.009.
39. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(suppl 1):II2-I10. doi: 10.1161/01. CIR.0000129535.04194.38.
40. Lin M, Lucas HC, Shmueli G. Research commentary: too big to fail: large samples and thep-value problem. Inf Syst Res. 2013;24:906-917. doi: 10.1287/isre.2013.0480.
41. Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Grad Med Educ. 2012;4:279-282. doi: 10.4300/JGME-D-12-00156.1.
42. Wasserstein RL, Lazar NA. The ASA's statement on p-values: context, process, and purpose. Am Stat. 2016;70:129-133. doi: 10.1080/00031305.2016.1154108.
43. Rezvanpour A, Shortt C, Clark L, Worster A, Kavsak PA. Analytical factors to consider when assessing a high-sensitivity cardiac troponin I assay compared to a contemporary assay in clinical studies. Clin Chim Acta. 2014;429:6-7. doi: 10.1016/j. cca.2013.11.012.
44. Dalen H, Thorstensen A, Romundstad PR, Aase SA, Stoylen A, Vatten LJ. Cardiovascular risk factors and systolic and diastolic cardiac function: a tissue Doppler and speckle tracking echocardiographic study. J Am Soc Echocardiogr. 2011;24:322-332.e6. doi: 10.1016/j.echo.2010.12.010.